CTLA4 and cancer: Other immune checkpoint receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have also been gaining more attention for use in monotherapy or in conjunction with other immunotherapies or conventional cancer therapeutics [44,45,46,47].